chief of cardiothoracic surgery Rhode Island Hospital

Printed as of 3/29/2024

## **Disclosures**

Personal	Commerc	cial (	<b>(7)</b>
i Ci Joilai	COIIIIICI	-iui i	

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self	if		
Allergen Pharma	Data Safety Monitoring Board	Modest (< \$5,000)	Cardiothoracic Surgery
CHIR (Canada) DSMB chair	Consultant Fees/Honoraria	None (\$0)	Cardiothoracic Surgery
Department of Defense	Other - steering committee for CHIPS trial	Modest (< \$5,000)	
NHLBI CTS Network	Data Safety Monitoring Board	Modest (< \$5,000)	Cardiothoracic Surgery
Octapharma	Data Safety Monitoring Board	Modest (< \$5,000)	Cardiothoracic Surgery
XM therapeutics	Ownership Interest/Partnership/Principal	None (\$0)	
xylocor	Consultant Fees/Honoraria	Modest (< \$5,000)	Cardiothoracic Surgery

#### Additional Personal Commercial Disclosures for Education Activities (1)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
xm therapeutics	Ownership Interest/Partnership/Principal	None (\$0)	Cardiothoracic Surgery

## Personal Organizational or Other Non-Commercial (1)

Non-Commercial Enity Name	Relationship Category	Compensation Level Topic Area(s)	
Self			
National Heart Lung and Blood Institute	Data Safety Monitoring Board	Modest (< \$5,000)	Cardiothoracic Surgery

# Clinical Trial Enroller (1)

Trial Name	Trial Sponsor	Trial Funding Source
Safe and Timely Antithrombotic Removal Ticagrelor (STAR-T)	Cytosorbent Medical, Inc	Same

## Institutional Financial Decision-Making Role (1)

Funding Source	Institutional Compensation Level
lifespan rhode island hospital	Significant (>= \$5,000)

#### Expert Witness Testimony (2)

Year	Case Title	Represented	Description	Compensation
Self				
2019	cardiac rupture	Defendant † insurance	purported inappropriate management	Significant (>= \$5,000)
2019	medical malpractice	Defendant † insurance	aortic rupture	Significant (>= \$5,000)

† Commercial Funding Source | ‡ Trial Name

## Agreement

Certified Education Attestation | Signed on 8/30/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/Certified Education Attest at ion Agreement and the property of the

Confidentiality, Disclosure and Assignment Agreement | Signed on 8/30/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 8/30/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

#### On-Going Obligation Agreement | Signed on 8/30/2023

## **ACC** and **Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.